- $11.72m
- $11.67m
- $41.71m
Brief: Biofrontera Inc. Announces Major Restructuring Of Relationship With Biofrontera AG Backed By $11 Million Investment
Biofrontera Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Biofrontera Announces New Patent Protection On Ameluz Until 2043
Biofrontera Inc expected to post a loss of 21 cents a share - Earnings Preview
Biofrontera Inc reports results for the quarter ended December 31 - Earnings Summary
Biofrontera Inc expected to post a loss of 2 cents a share - Earnings Preview
Biofrontera Inc expected to post a loss of 2 cents a share - Earnings Preview
Brief: Biofrontera Achieves Key Milestone In Phase 3 Study Of Ameluz-PDT In Treatment Of sBCC
Biofrontera's US-listed shares fall as Q3 revenue misses estimates
Biofrontera Inc reports results for the quarter ended September 30 - Earnings Summary
Biofrontera Inc expected to post a loss of 83 cents a share - Earnings Preview
Brief: Biofrontera Inc. Announces Positive Phase 3 Results
Brief: Biofrontera Inc - Data Now Being Analyzed, Interim Results Expected November 2024
Biofrontera Inc reports results for the quarter ended in June - Earnings Summary
Biofrontera Inc expected to post a loss of 77 cents a share - Earnings Preview
Biofrontera Inc expected to post a loss of 77 cents a share - Earnings Preview
Brief: Biofrontera AG Says Legal Dispute On Import In USA Will Result In Revised Outlook
Biofrontera Inc expected to post a loss of $1.17 a share - Earnings Preview
Biofrontera Inc reports results for the quarter ended in December - Earnings Summary